🏛️ Verified NIH Record • Updated 2026-06-08

Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC (NCT05798663)

Randomized Phase II Trial of Neoadjuvant and Adjuvant Atezolizumab With or Without Tiragolumab in Conjunction With Chemoradiotherapy for Unresectable Stage III NSCLC

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Alliance Foundation Trials, LLC.

🩺 Plain-English Summary (8th-Grade Level)

This is a phase II trial of neoadjuvant and adjuvant atezolizumab with or without tiragolumab in conjunction with chemoradiotherapy for unresectable stage III NSCLC.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (54 items) and avoid the listed exclusions (58 items).

Location: University of California San Diego Moores Cancer Center — La Jolla, California

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Active autoimmune disease.
  • Greater than minimal, exudative, or cytologically positive pleural effusions.
  • Involved contralateral hilar nodes.
  • More than 10% unintentional weight loss within the past month.
  • Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years; non-invasive conditions such as carcinoma in situ of the breast, localized prostate cancer or thyroid nodules, carcinoma in situ of the oral cavity or cervix are all permissible.
  • Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable.
  • Prior radiotherapy to the region of the study cancer that would result in clinically significant overlap of radiation therapy fields.
  • Prior severe infusion reaction to a monoclonal antibody.
  • Significant history of uncontrolled cardiac disease; i.e., uncontrolled hypertension, unstable angina, myocardial infarction within the last 6 months, uncontrolled congestive heart failure, and cardiomyopathy with decreased ejection fraction.
  • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration or within 2 weeks of cycle 1 day 1.
  • Severe active infection, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that, in the opinion of the investigator, could impact patient safety

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (15 Sites)

  • University of California San Diego Moores Cancer Center — La Jolla, California
  • Kaiser Permanente Oakland Medical Center — Oakland, California
  • Kaiser Permanente Roseville Medical Center — Roseville, California
  • Kaiser Permanente San Francisco Medical Center — San Francisco, California
  • Kaiser Permanente Santa Clara Medical Center — Santa Clara, California
  • Kaiser Permanente Vallejo Medical Center — Vallejo, California
  • Rush University Medical Center — Chicago, Illinois
  • Washington University Siteman Cancer Center — St Louis, Missouri
  • Missouri Baptist Medical Center — St Louis, Missouri
  • University of Nebraska Medical Center — Omaha, Nebraska
  • New Hampshire Oncology - Hematology, PA — Manchester, New Hampshire
  • Hematology Oncology Associates of Central New York, P.C. — East Syracuse, New York
  • SUNY Upstate Medical University — Syracuse, New York
  • Ohio State University — Columbus, Ohio
  • University of Wisconsin — Madison, Wisconsin

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in NSCLC

Explore by condition: All NSCLC clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗